Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biocept, Inc. (BIOC : NSDQ)
 
 • Company Description   
Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California.

Number of Employees: 177

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.37 Daily Weekly Monthly
20 Day Moving Average: 93,211 shares
Shares Outstanding: 16.92 (millions)
Market Capitalization: $23.18 (millions)
Beta: 0.66
52 Week High: $4.97
52 Week Low: $1.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.18% -7.65%
12 Week -39.11% -32.87%
Year To Date -62.15% -54.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9955 Mesa Rim Road
-
San Diego,CA 92121
USA
ph: 858-320-8200
fax: 858-320-8225
ir@biocept.com http://www.abcoenergy.com
 
 • General Corporate Information   
Officers
Samuel D. Riccitelli - Interim Chief Executive Officer; President; Chairm
Antonino Morales - Interim Chief Financial Officer and Director
M. Faye Wilson - Director
Marsha A. Chandler - Director
David F. Hale - Director

Peer Information
Biocept, Inc. (CHCR)
Biocept, Inc. (ESRX)
Biocept, Inc. (MYDP)
Biocept, Inc. (GBCS)
Biocept, Inc. (LAXAF)
Biocept, Inc. (IPCM)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 09072V501
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 16.92
Most Recent Split Date: 9.00 (0.10:1)
Beta: 0.66
Market Capitalization: $23.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.63
Price/Cash Flow: -
Price / Sales: 0.37
EPS Growth
vs. Year Ago Period: -184.21%
vs. Previous Quarter: 11.11%
Sales Growth
vs. Year Ago Period: 12.33%
vs. Previous Quarter: 42.71%
ROE
03/31/22 - -19.99
12/31/21 - -5.35
09/30/21 - 10.44
ROA
03/31/22 - -12.16
12/31/21 - -3.17
09/30/21 - 5.90
Current Ratio
03/31/22 - 3.38
12/31/21 - 3.88
09/30/21 - 4.12
Quick Ratio
03/31/22 - -
12/31/21 - 3.66
09/30/21 - 4.26
Operating Margin
03/31/22 - -11.25
12/31/21 - -2.89
09/30/21 - 4.71
Net Margin
03/31/22 - -11.26
12/31/21 - -2.89
09/30/21 - 4.71
Pre-Tax Margin
03/31/22 - -12.72
12/31/21 - -4.41
09/30/21 - 3.11
Book Value
03/31/22 - 2.19
12/31/21 - 2.23
09/30/21 - 2.65
Inventory Turnover
03/31/22 - 13.27
12/31/21 - 12.77
09/30/21 - 13.60
Debt-to-Equity
03/31/22 - 0.03
12/31/21 - 0.04
09/30/21 - 0.04
Debt-to-Capital
03/31/22 - 3.19
12/31/21 - 3.67
09/30/21 - 4.01
 

Powered by Zacks Investment Research ©